Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma

PURPOSE: MYCN-dependent neuroblastomas have low cure rates with current multimodal treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous pre-clinical studies we have shown that targeted inhibition of cyclin-dependent kinase 2 (CDK2) resulted in specific killing of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Dolman, M. Emmy M., Poon, Evon, Ebus, Marli E., den Hartog, Ilona J.M., van Noesel, Carel J.M., Jamin, Yann, Hallsworth, Albert, Robinson, Simon P., Petrie, Kevin, Sparidans, Rolf W., Kok, Robbert J., Versteeg, Rogier, Caron, Huib N., Chesler, Louis, Molenaar, Jan J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4645454/
https://ncbi.nlm.nih.gov/pubmed/26202950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0313
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg